DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for generalized dystonia — screening already-approved drugs against its 28-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralized dystonia maps to a 28-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalized dystonia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dual specificity phosphatase 22 (DUSP22) — DUSP22 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4npdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4WOH · 1.34 Å · ligand 4-NITROPHENYL PHOSPHATE (4NP). Experimental structure, not a prediction.
What the evidence adds up to
The available literature on generalized dystonia is dominated by reviews and consensus statements rather than controlled trials of specific drugs. A 2009 treatment review lists physical and occupational therapy, oral medications, intramuscular botulinum toxin injections, and neurosurgical interventions as the available options, and states plainly that the therapeutic approach is usually limited to symptomatic therapy tailored to the individual patient. No quantitative efficacy data for any oral drug in generalized dystonia are reported in these abstracts. A 2001 family study of a GCH1 gene mutation, which causes a levodopa-responsive dystonia, examined 11 affected family members and found wide variability of motor dysfunction, with roughly 50% having clinical deafness and a similar proportion showing depression or anxiety; the authors note that important clinical features may be unrecognised and thus inappropriately managed, but they provide no treatment outcome data.
The pathophysiological reviews converge on three proposed mechanisms: loss of inhibition at multiple levels of the central nervous system, faulty sensory-motor integration in the lemniscal pathway, and abnormal maladaptive neuroplasticity triggered by environmental factors such as repetitive training or peripheral injury. A 2011 review argues that shared mechanisms across etiologically diverse dystonias exist at the cellular level (dopaminergic system, mitochondrial function, calcium regulation), at the anatomical level (basal ganglia and cerebellum), and globally (aberrant plasticity, inhibition, sensorimotor integration). These are hypotheses for future drug targets, not evidence of drug efficacy. A 2013 review identifies five new genes for primary dystonia (PRRT2, CIZ1, ANO3, TUBB4A, GNAL) and a new treatable form of dystonia with brain manganese deposition linked to SLC30A10 mutations, but again provides no clinical trial results.
The diagnostic literature stresses that recognition of dystonia is underestimated and that proper classification is essential for therapeutic decisions. A 2004 review of childhood dystonia describes an NIH-funded consensus definition from January 2003 and reports that biomechanical, kinematic, and surface EMG measurements show promise for providing specific and sensitive measures, but these are validation studies, not treatment trials. Across all abstracts, there is no randomised controlled trial, no response rate, no survival statistic, and no comparison of drug versus placebo for generalized dystonia. The field lacks prospective clinical data on drug repurposing candidates; what is missing is a properly powered trial with validated outcome measures, patient stratification by genetic cause, and long-term follow-up, none of which the current literature supplies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Movement Disorders · 2013 · 214 citations
The focal dystonias: Current views and challenges for future research
AbstractThe most common forms of dystonia are those that develop in adults and affect a relatively isolated region of the body. Although these adult-onset focal dystonias are most prevalent, knowledge of their etiologies and pathogenesis has lagged behind some of the rarer generalized dystonias, in which the identification of genetic defects has facilitated both basic and clinical research. This summary provides a brief review of the clinical manifestations of the adult-onset focal dystonias, focusing attention on less well understood clinical manifestations that need further study. It also provides a simple conceptual model for the similarities and differences among the different adult-onset focal dystonias as a rationale for lumping them together as a class of disorders while at the same time splitting them into subtypes. The concluding section outlines some of the most important research questions for the future. Answers to these questions are critical for advancing our understanding of this group of disorders and for developing novel therapeutics.
Expert Opinion on Pharmacotherapy · 2009 · 113 citations
Treatment strategies for dystonia
AbstractIMPORTANCE OF THE FIELD: Dystonia is a neurological syndrome characterized by involuntary twisting movements and unnatural postures. It has many different manifestations and causes, and many different treatment options are available. These options include physical and occupational therapy, oral medications, intramuscular injection of botulinum toxins, and neurosurgical interventions. AREAS COVERED IN THIS REVIEW: In this review, we first summarize the treatment options available, then we provide suggestions from our own experience for how these can be applied in different types of dystonia. In preparing this review article, an extensive literature search was undertaken using PubMed. Only selected references from 1970 to 2008 are cited. WHAT THE READER WILL GAIN: This review is intended to provide the clinician with a practical guide to the treatment of dystonia. TAKE HOME MESSAGE: Treatment of dystonia begins with proper diagnosis and classification, followed by an appropriate search for underlying etiology, and an assessment of the functional impairment associated with the dystonia. The therapeutic approach, which is usually limited to symptomatic therapy, must then be tailored to the individual needs of the patient.
Current Opinion in Neurology · 2008 · 80 citations
Clinical features of dystonia: a pathophysiological revisitation
AbstractPURPOSE OF REVIEW: To elucidate the pathophysiology of some clinical features of dystonic patients and to provide some new insight into the mechanisms underlying task-specific dystonia. RECENT FINDINGS: There are three general lines of work at the present time that may indicate the physiological substrate for dystonia. All three are persuasive and it is not clear whether they are related to each other or whether one is more important than the others. According to the first line of research, a loss of inhibition at different levels of the central nervous system might contribute for the excessive movement seen in dystonia. Another field of research suggests that dystonic patients may have faulty processing within the lemniscal pathway with abnormalities in the sensory-motor integration. Finally, another convincing line of evidence is that in some susceptible individuals, during the acquisition of new motor skills, the mechanisms of neuroplasticity are subtly abnormal. In the presence of such predisposition, several environmental factors, such as repetitive training or peripheral nervous system injury, can trigger an abnormal maladaptive plasticity, which can lead to an overt dystonia. SUMMARY: These findings may be relevant in the development of new therapeutic strategies in dystonia.
Neurologic and Psychiatric Manifestations in a Family With a Mutation in Exon 2 of the Guanosine Triphosphate–Cyclohydrolase Gene
AbstractOBJECTIVE: To investigate the range of clinical features to correlate genotypic and phenotypic manifestations in hereditary progressive and/or levodopa-responsive dystonia due to a defect in the guanosine triphosphate-cyclohydrolase (GCH1) gene. DESIGN AND SETTING: A large family from Texas was studied in an ambulatory setting by clinicians in genetics, neurology, and psychiatry using structured interviews and examinations. PATIENTS: The family was selected after neurometabolic investigations of a young boy (proband) with foot dystonia and fatigue and his father, who had a long history of anxiety and depression. Results of metabolic studies showed decreased levels of metabolites of biopterin and biogenic amines in cerebrospinal fluid. Subsequently, a novel mutation (37-base pair deletion) in exon 2 of the GCH1 gene was demonstrated in 11 family members. There was no observed female sex bias, but there was a wide variability of motor dysfunctions in family members. Approximately 50% had clinical deafness and a similar number had significant psychiatric dysfunction, including depression and anxiety. CONCLUSION: Study of additional families with hereditary progressive and/or levodopa-responsive dystonia using modern molecular methods will be necessary to confirm the neuropsychiatric spectrum of this disorder, in which important clinical features may be unrecognized and thus inappropriately managed.
Current Opinion in Pediatrics · 2004 · 39 citations
Toward a definition of childhood dystonia
AbstractPURPOSE OF REVIEW: The purpose of this review is to summarize recent progress toward providing a consistent, sensitive, specific, and useful definition of dystonia as it presents in childhood. RECENT FINDINGS: An NIH-funded consensus group published a definition of childhood dystonia in January of 2003. Recent work has attempted to identify quantitative methods for diagnosis and measurement of childhood dystonia. Techniques include biomechanical, kinematic, and surface EMG measurements that show promise for providing specific and sensitive measures of childhood dystonia. SUMMARY: The results of current research efforts will be useful for verifying and modifying definitions of dystonia to provide consistent and measurable terms for including children in research trials and selecting appropriate interventions for clinical treatment.
Expert Opinion on Therapeutic Targets · 2011 · 31 citations · open access
Convergent mechanisms in etiologically-diverse dystonias
AbstractINTRODUCTION: Dystonia is a neurological disorder associated with twisting motions and abnormal postures, which compromise normal movements and can be both painful and debilitating. It can affect a single body part (focal), several contiguous regions (segmental), or the entire body (generalized), and can arise as a result of numerous causes, both genetic and acquired. Despite the diversity of causes and manifestations, shared clinical features suggest that common mechanisms of pathogenesis may underlie many dystonias. AREAS COVERED: Shared themes in etiologically-diverse dystonias exist at several biological levels. At the cellular level, abnormalities in the dopaminergic system, mitochondrial function and calcium regulation are often present. At the anatomical level, the basal ganglia and the cerebellum are frequently implicated. Global CNS dysfunction, specifically aberrant neuronal plasticity, inhibition and sensorimotor integration, are also observed in a number of dystonias. Using clinical data and data from animal models, this article seeks to highlight shared pathways that may be critical in understanding mechanisms and identifying novel therapeutic strategies in dystonia. EXPERT OPINION: Identifying shared features of pathogenesis can provide insight into the biological processes that underlie etiologically diverse dystonias, and can suggest novel targets for therapeutic intervention that may be effective in a broad group of affected individuals.
Current Opinion in Neurology · 2013 · 14 citations · open access
Primary and secondary dystonic syndromes
AbstractPURPOSE OF REVIEW: The dystonias are a common but complex group of disorders that show considerable variation in cause and clinical presentation. The purpose of this review is to highlight the most important discoveries and insights from across the field over the period of the past 18 months. RECENT FINDINGS: Five new genes for primary dystonia (PRRT2, CIZ1, ANO3, TUBB4A and GNAL) have made their appearance in the literature. New subtypes of neuronal brain iron accumulation have been delineated and linked to mutations in C19orf12 and WDR45, while a new treatable form of dystonia with brain manganese deposition related to mutations in SLC30A10 has been described. At the same time, the phenotypes of other forms of dystonic syndromes have been expanded or linked together. Finally, there has been increasing recognition of both the extramotor phenotype in dystonia and the part played by the cerebellum in its pathophysiology. SUMMARY: Recently, there has been unprecedented change in the scientific landscape with respect to the cause of various dystonic syndromes that is likely to make a direct impact on clinical practice in the near future. Understanding the genetic cause of these syndromes and the often wide phenotypic variation in their presentations will improve diagnosis and treatment. With time, these discoveries may also lead to much-needed progress in elucidating the underlying pathophysiology of dystonia.
Expert Opinion on Medical Diagnostics · 2011 · 3 citations
Diagnostic issues in childhood and adult dystonia
AbstractINTRODUCTION: There is a general agreement among movement disorder specialists that the recognition of dystonia may be underestimated. In parallel, the growing interest and the improving knowledge of genetic and physiopathological aspects of dystonias require systematization. AREAS COVERED: This review focuses on the phenomenology and etiology of pediatric and adult dystonias. It is designed to provide practical help for neurologists and neuropediatricians to make appropriate diagnoses and plan the therapeutical management of these disorders. The reader will get a systematization of the main etiological and diagnostic aspects that differentiate child-onset from adult-onset dystonias. The reader will also gain insights into specific treatments or cures. EXPERT OPINION: Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
